ArticleFrontiers in oncology2022

Safety and Efficacy of Sintilimab and Anlotinib as First Line Treatment for Advanced Hepatocellular Carcinoma (KEEP-G04): A Single-Arm Phase 2 Study.

Xiaofeng Chen et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.